Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS

Table 4 Multivariate Cox regression models for target lesion failure and major adverse cardiac events

A. Variable for outcome TLF	Hazard ratio	95% CI	P-value
Age at device implantation	1.03	0.99–1.06	0.12
Insulin-treated diabetes mellitus	1.82	0.97–3.41	0.06
Number of treated vessels	1.17	0.47–2.91	0.74
Total treated length	1.00	0.99–1.02	0.84
EE-BRS vs. EES	1.48	0.77–2.87	0.24

B. Variable for outcome MACE	Hazard ratio	95% CI	p-value
Age at device implantation	1.03	1.00–1.05	0.06
Insulin-treated diabetes mellitus	1.40	0.82–2.37	0.22
Number of treated vessels	1.57	0.77–3.22	0.22
Total treated length	1.00	0.99–1.01	0.88
EE-BRS vs. EES	1.23	0.70–2.17	0.47

Section A. Multivariate Cox regression model for target lesion failure adjusted for age, insulin-treated diabetes mellitus, number of treated vessels, total treated length and destined treatment group
Section B. The same model calculated for major adverse cardiac events. Risk factors are given in hazard ratios with 95% confidence intervals with corresponding p-values
A p-value < 0.05 was considered as statistically significant. No significant differences between both everolimus-eluting bioresorbable scaffolds and everolimus-eluting stents treatment groups were ascertained. Insulin-treatment for diabetes mellitus was the only variable that showed a trend as predictor for target lesion failure as was age for major adverse cardiac events
TLF target lesion failure, CI confidence interval, EE-BRS everolimus-eluting bioresorbable scaffolds, EES everolimus-eluting stents, MACE major adverse cardiac events

ISSN: 1475-2840